You just read:

Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

17 Oct, 2018, 13:00 BST